STOCK TITAN

[Form 4] Insmed, Inc. Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Very Negative)
Form Type
4
Rhea-AI Filing Summary

Waystar Holding Corp. (WAY) signed a $1.25 billion agreement to acquire Iodine Software on 23-Jul-2025.

The definitive Agreement and Plan of Merger calls for roughly $625 million in cash plus 16,751,54 newly issued common shares (par $0.01) to Iodine equity-holders. The transaction will be executed through Reverse and Forward Merger Subs, with Forward Merger Sub surviving.

Boards of both companies and Iodine’s sole equity-holder have unanimously approved the deal. Closing is subject to customary conditions, including HSR clearance, accuracy of representations, covenant compliance and no material adverse effect at Iodine. Either party may terminate if the merger is not completed by 23-Nov-2025.

Related agreements include: (i) a Stockholder & Lock-up Agreement restricting share transfers for 6-18 months post-close and granting Advent International one board seat while it owns ≥5% of shares; (ii) an amendment increasing Waystar’s board size from 12 to 13 to accommodate the Advent nominee; and (iii) a Joinder to the Registration Rights Agreement giving Advent two short-form demand registrations and piggyback rights 18 months after close.

A press release with preliminary Q2-FY25 results was furnished as Exhibit 99.1 under Items 2.02 and 7.01.

Waystar Holding Corp. (WAY) ha firmato un accordo da 1,25 miliardi di dollari per acquisire Iodine Software il 23 luglio 2025.

L'Accordo Definitivo e il Piano di Fusione prevedono circa 625 milioni di dollari in contanti più 16.751.540 nuove azioni ordinarie emesse (valore nominale $0,01) per gli azionisti di Iodine. L'operazione sarà eseguita tramite società di fusione Reverse e Forward, con la Forward Merger Sub che sopravviverà.

I consigli di amministrazione di entrambe le società e l'unico azionista di Iodine hanno approvato all'unanimità l'accordo. La chiusura è subordinata a condizioni consuete, tra cui l'approvazione HSR, la correttezza delle dichiarazioni, il rispetto degli impegni e l'assenza di effetti negativi materiali su Iodine. Qualsiasi parte può rescindere se la fusione non sarà completata entro il 23 novembre 2025.

Gli accordi correlati includono: (i) un Accordo Azionisti e Lock-up che limita il trasferimento delle azioni per 6-18 mesi dopo la chiusura e concede ad Advent International un seggio nel consiglio finché detiene ≥5% delle azioni; (ii) una modifica che aumenta il numero dei membri del consiglio di Waystar da 12 a 13 per accogliere il candidato di Advent; e (iii) un'adesione all'Accordo sui Diritti di Registrazione che concede ad Advent due registrazioni di domanda in forma abbreviata e diritti piggyback 18 mesi dopo la chiusura.

Un comunicato stampa con i risultati preliminari del secondo trimestre dell'anno fiscale 2025 è stato presentato come Allegato 99.1 ai sensi degli Articoli 2.02 e 7.01.

Waystar Holding Corp. (WAY) firmó un acuerdo de 1.250 millones de dólares para adquirir Iodine Software el 23 de julio de 2025.

El Acuerdo Definitivo y Plan de Fusión contempla aproximadamente 625 millones de dólares en efectivo más 16.751.540 nuevas acciones ordinarias emitidas (valor nominal $0.01) para los accionistas de Iodine. La transacción se ejecutará a través de subsidiarias de fusión inversa y directa, con la Forward Merger Sub como entidad sobreviviente.

Los consejos de administración de ambas compañías y el único accionista de Iodine han aprobado unánimemente el acuerdo. El cierre está sujeto a condiciones habituales, incluyendo la aprobación HSR, exactitud de las representaciones, cumplimiento de convenios y ausencia de efectos adversos materiales en Iodine. Cualquiera de las partes puede cancelar si la fusión no se completa antes del 23 de noviembre de 2025.

Los acuerdos relacionados incluyen: (i) un Acuerdo de Accionistas y Lock-up que restringe la transferencia de acciones por 6-18 meses post-cierre y otorga a Advent International un asiento en el consejo mientras posea ≥5% de las acciones; (ii) una enmienda que incrementa el tamaño del consejo de Waystar de 12 a 13 para acomodar al nominado de Advent; y (iii) una adhesión al Acuerdo de Derechos de Registro que otorga a Advent dos registros de demanda en formato corto y derechos piggyback 18 meses después del cierre.

Un comunicado de prensa con resultados preliminares del segundo trimestre del año fiscal 2025 fue presentado como Anexo 99.1 bajo los ítems 2.02 y 7.01.

Waystar Holding Corp.(WAY)는 2025년 7월 23일 Iodine Software를 12억 5천만 달러에 인수하는 계약을 체결했습니다.

최종 합병 계약서에는 약 6억 2,500만 달러 현금과 16,751,540주의 신주(액면가 $0.01)를 Iodine 주주에게 지급하는 내용이 포함되어 있습니다. 거래는 리버스 및 포워드 합병 자회사를 통해 진행되며, 포워드 합병 자회사가 존속합니다.

양사 이사회와 Iodine의 단일 주주는 만장일치로 거래를 승인했습니다. 거래 완료는 HSR 승인, 진술의 정확성, 계약 준수, Iodine에 중대한 부정적 영향 없음 등 일반적인 조건 충족 시 가능합니다. 합병이 2025년 11월 23일까지 완료되지 않으면 어느 쪽도 계약을 해지할 수 있습니다.

관련 계약에는 (i) 인수 후 6~18개월간 주식 이전을 제한하고 Advent International이 ≥5% 지분 보유 시 이사회 의석을 부여하는 주주 및 락업 계약, (ii) Advent 지명자를 수용하기 위해 Waystar 이사회 규모를 12명에서 13명으로 늘리는 수정안, (iii) 인수 후 18개월 후에 Advent에 두 차례 단기 청구 등록 및 피기백 권리를 부여하는 등록 권리 계약 가입서가 포함됩니다.

2025 회계연도 2분기 잠정 실적을 담은 보도자료가 2.02 및 7.01 항목에 따라 증거자료 99.1로 제출되었습니다.

Waystar Holding Corp. (WAY) a signé un accord de 1,25 milliard de dollars pour acquérir Iodine Software le 23 juillet 2025.

L'Accord Définitif et le Plan de Fusion prévoient environ 625 millions de dollars en espèces ainsi que 16 751 540 actions ordinaires nouvellement émises (valeur nominale 0,01 $) aux actionnaires d'Iodine. La transaction sera réalisée via des filiales de fusion inversée et directe, la Forward Merger Sub survivant.

Les conseils d'administration des deux sociétés ainsi que l'unique actionnaire d'Iodine ont approuvé à l'unanimité l'accord. La clôture est soumise aux conditions habituelles, notamment l'approbation HSR, l'exactitude des déclarations, le respect des engagements et l'absence d'effet défavorable important chez Iodine. Chaque partie peut résilier si la fusion n'est pas finalisée avant le 23 novembre 2025.

Les accords connexes comprennent : (i) un Accord d'Actionnaires et de Blocage limitant les transferts d'actions pendant 6 à 18 mois après la clôture et accordant à Advent International un siège au conseil tant qu'elle détient ≥5 % des actions ; (ii) un amendement augmentant la taille du conseil d'administration de Waystar de 12 à 13 membres pour accueillir le candidat d'Advent ; et (iii) une adhésion à l'Accord sur les Droits d'Enregistrement accordant à Advent deux enregistrements de demande en forme abrégée et des droits piggyback 18 mois après la clôture.

Un communiqué de presse présentant les résultats préliminaires du deuxième trimestre de l'exercice 2025 a été fourni en tant que pièce 99.1 conformément aux articles 2.02 et 7.01.

Waystar Holding Corp. (WAY) unterzeichnete am 23. Juli 2025 eine Vereinbarung zum Erwerb von Iodine Software im Wert von 1,25 Milliarden US-Dollar.

Der endgültige Fusionsvertrag sieht rund 625 Millionen US-Dollar in bar sowie 16.751.540 neu ausgegebene Stammaktien (Nennwert 0,01 USD) für die Iodine-Aktionäre vor. Die Transaktion wird über Reverse- und Forward-Merger-Subs durchgeführt, wobei die Forward Merger Sub überlebt.

Die Vorstände beider Unternehmen und der alleinige Anteilseigner von Iodine haben die Vereinbarung einstimmig genehmigt. Der Abschluss unterliegt üblichen Bedingungen, darunter die HSR-Freigabe, die Richtigkeit der Zusicherungen, die Einhaltung von Verpflichtungen und das Fehlen wesentlicher nachteiliger Auswirkungen bei Iodine. Jede Partei kann die Vereinbarung kündigen, falls die Fusion nicht bis zum 23. November 2025 abgeschlossen ist.

Zugehörige Vereinbarungen umfassen: (i) eine Aktionärs- und Lock-up-Vereinbarung, die die Übertragung von Aktien für 6-18 Monate nach Abschluss einschränkt und Advent International einen Sitz im Vorstand gewährt, solange es ≥5% der Aktien hält; (ii) eine Änderung, die die Größe des Waystar-Vorstands von 12 auf 13 erhöht, um den Advent-Nominierten aufzunehmen; und (iii) einen Beitritt zur Registrierungsrechtsvereinbarung, der Advent zwei Kurzform-Anmeldeanmeldungen und Piggyback-Rechte 18 Monate nach Abschluss gewährt.

Eine Pressemitteilung mit vorläufigen Ergebnissen des zweiten Quartals des Geschäftsjahres 2025 wurde als Anlage 99.1 gemäß den Punkten 2.02 und 7.01 eingereicht.

Positive
  • $1.25 bn acquisition expands Waystar’s product suite and market reach.
  • Balanced consideration of cash and stock limits leverage increase.
  • Unanimous board approvals reduce governance uncertainty.
  • Lock-up periods (6-18 months) mitigate immediate share overhang.
Negative
  • Share issuance will dilute existing shareholders once lock-ups expire.
  • Regulatory/Hart-Scott-Rodino clearance could delay or block closing.
  • Termination date of 23-Nov-2025 adds time pressure and deal-break risk.

Insights

TL;DR: $1.25 bn cash-and-stock deal adds scale; terms appear standard, lock-ups mitigate immediate selling pressure.

The acquisition price implies meaningful strategic value for Waystar, doubling down on clinical documentation and AI capabilities. Cash outlay ($625 m) is balanced by equity, limiting leverage impact but introducing dilution. Board-approved, the agreement contains customary covenants and a four-month outside date, signalling confidence in regulatory clearance. Advent’s 5% threshold board right is typical of PE involvement and the lock-up periods (6-18 months) reduce near-term float expansion. Overall, execution risk centres on HSR clearance and integration; otherwise, the transaction should be accretive operationally.

TL;DR: Deal is strategically positive but adds dilution and execution risk; impact judged moderately positive.

Waystar gains a complementary software platform at a negotiated $1.25 bn enterprise value. While the cash component is sizable, the mixed consideration preserves liquidity. Share issuance will dilute existing holders, yet staggered lock-ups and Advent’s board seat align incentives. Termination by 23-Nov-2025 keeps timeline tight; failure to close would reverse anticipated synergies. Investors should monitor regulatory milestones and forthcoming pro-forma financials once disclosed.

Waystar Holding Corp. (WAY) ha firmato un accordo da 1,25 miliardi di dollari per acquisire Iodine Software il 23 luglio 2025.

L'Accordo Definitivo e il Piano di Fusione prevedono circa 625 milioni di dollari in contanti più 16.751.540 nuove azioni ordinarie emesse (valore nominale $0,01) per gli azionisti di Iodine. L'operazione sarà eseguita tramite società di fusione Reverse e Forward, con la Forward Merger Sub che sopravviverà.

I consigli di amministrazione di entrambe le società e l'unico azionista di Iodine hanno approvato all'unanimità l'accordo. La chiusura è subordinata a condizioni consuete, tra cui l'approvazione HSR, la correttezza delle dichiarazioni, il rispetto degli impegni e l'assenza di effetti negativi materiali su Iodine. Qualsiasi parte può rescindere se la fusione non sarà completata entro il 23 novembre 2025.

Gli accordi correlati includono: (i) un Accordo Azionisti e Lock-up che limita il trasferimento delle azioni per 6-18 mesi dopo la chiusura e concede ad Advent International un seggio nel consiglio finché detiene ≥5% delle azioni; (ii) una modifica che aumenta il numero dei membri del consiglio di Waystar da 12 a 13 per accogliere il candidato di Advent; e (iii) un'adesione all'Accordo sui Diritti di Registrazione che concede ad Advent due registrazioni di domanda in forma abbreviata e diritti piggyback 18 mesi dopo la chiusura.

Un comunicato stampa con i risultati preliminari del secondo trimestre dell'anno fiscale 2025 è stato presentato come Allegato 99.1 ai sensi degli Articoli 2.02 e 7.01.

Waystar Holding Corp. (WAY) firmó un acuerdo de 1.250 millones de dólares para adquirir Iodine Software el 23 de julio de 2025.

El Acuerdo Definitivo y Plan de Fusión contempla aproximadamente 625 millones de dólares en efectivo más 16.751.540 nuevas acciones ordinarias emitidas (valor nominal $0.01) para los accionistas de Iodine. La transacción se ejecutará a través de subsidiarias de fusión inversa y directa, con la Forward Merger Sub como entidad sobreviviente.

Los consejos de administración de ambas compañías y el único accionista de Iodine han aprobado unánimemente el acuerdo. El cierre está sujeto a condiciones habituales, incluyendo la aprobación HSR, exactitud de las representaciones, cumplimiento de convenios y ausencia de efectos adversos materiales en Iodine. Cualquiera de las partes puede cancelar si la fusión no se completa antes del 23 de noviembre de 2025.

Los acuerdos relacionados incluyen: (i) un Acuerdo de Accionistas y Lock-up que restringe la transferencia de acciones por 6-18 meses post-cierre y otorga a Advent International un asiento en el consejo mientras posea ≥5% de las acciones; (ii) una enmienda que incrementa el tamaño del consejo de Waystar de 12 a 13 para acomodar al nominado de Advent; y (iii) una adhesión al Acuerdo de Derechos de Registro que otorga a Advent dos registros de demanda en formato corto y derechos piggyback 18 meses después del cierre.

Un comunicado de prensa con resultados preliminares del segundo trimestre del año fiscal 2025 fue presentado como Anexo 99.1 bajo los ítems 2.02 y 7.01.

Waystar Holding Corp.(WAY)는 2025년 7월 23일 Iodine Software를 12억 5천만 달러에 인수하는 계약을 체결했습니다.

최종 합병 계약서에는 약 6억 2,500만 달러 현금과 16,751,540주의 신주(액면가 $0.01)를 Iodine 주주에게 지급하는 내용이 포함되어 있습니다. 거래는 리버스 및 포워드 합병 자회사를 통해 진행되며, 포워드 합병 자회사가 존속합니다.

양사 이사회와 Iodine의 단일 주주는 만장일치로 거래를 승인했습니다. 거래 완료는 HSR 승인, 진술의 정확성, 계약 준수, Iodine에 중대한 부정적 영향 없음 등 일반적인 조건 충족 시 가능합니다. 합병이 2025년 11월 23일까지 완료되지 않으면 어느 쪽도 계약을 해지할 수 있습니다.

관련 계약에는 (i) 인수 후 6~18개월간 주식 이전을 제한하고 Advent International이 ≥5% 지분 보유 시 이사회 의석을 부여하는 주주 및 락업 계약, (ii) Advent 지명자를 수용하기 위해 Waystar 이사회 규모를 12명에서 13명으로 늘리는 수정안, (iii) 인수 후 18개월 후에 Advent에 두 차례 단기 청구 등록 및 피기백 권리를 부여하는 등록 권리 계약 가입서가 포함됩니다.

2025 회계연도 2분기 잠정 실적을 담은 보도자료가 2.02 및 7.01 항목에 따라 증거자료 99.1로 제출되었습니다.

Waystar Holding Corp. (WAY) a signé un accord de 1,25 milliard de dollars pour acquérir Iodine Software le 23 juillet 2025.

L'Accord Définitif et le Plan de Fusion prévoient environ 625 millions de dollars en espèces ainsi que 16 751 540 actions ordinaires nouvellement émises (valeur nominale 0,01 $) aux actionnaires d'Iodine. La transaction sera réalisée via des filiales de fusion inversée et directe, la Forward Merger Sub survivant.

Les conseils d'administration des deux sociétés ainsi que l'unique actionnaire d'Iodine ont approuvé à l'unanimité l'accord. La clôture est soumise aux conditions habituelles, notamment l'approbation HSR, l'exactitude des déclarations, le respect des engagements et l'absence d'effet défavorable important chez Iodine. Chaque partie peut résilier si la fusion n'est pas finalisée avant le 23 novembre 2025.

Les accords connexes comprennent : (i) un Accord d'Actionnaires et de Blocage limitant les transferts d'actions pendant 6 à 18 mois après la clôture et accordant à Advent International un siège au conseil tant qu'elle détient ≥5 % des actions ; (ii) un amendement augmentant la taille du conseil d'administration de Waystar de 12 à 13 membres pour accueillir le candidat d'Advent ; et (iii) une adhésion à l'Accord sur les Droits d'Enregistrement accordant à Advent deux enregistrements de demande en forme abrégée et des droits piggyback 18 mois après la clôture.

Un communiqué de presse présentant les résultats préliminaires du deuxième trimestre de l'exercice 2025 a été fourni en tant que pièce 99.1 conformément aux articles 2.02 et 7.01.

Waystar Holding Corp. (WAY) unterzeichnete am 23. Juli 2025 eine Vereinbarung zum Erwerb von Iodine Software im Wert von 1,25 Milliarden US-Dollar.

Der endgültige Fusionsvertrag sieht rund 625 Millionen US-Dollar in bar sowie 16.751.540 neu ausgegebene Stammaktien (Nennwert 0,01 USD) für die Iodine-Aktionäre vor. Die Transaktion wird über Reverse- und Forward-Merger-Subs durchgeführt, wobei die Forward Merger Sub überlebt.

Die Vorstände beider Unternehmen und der alleinige Anteilseigner von Iodine haben die Vereinbarung einstimmig genehmigt. Der Abschluss unterliegt üblichen Bedingungen, darunter die HSR-Freigabe, die Richtigkeit der Zusicherungen, die Einhaltung von Verpflichtungen und das Fehlen wesentlicher nachteiliger Auswirkungen bei Iodine. Jede Partei kann die Vereinbarung kündigen, falls die Fusion nicht bis zum 23. November 2025 abgeschlossen ist.

Zugehörige Vereinbarungen umfassen: (i) eine Aktionärs- und Lock-up-Vereinbarung, die die Übertragung von Aktien für 6-18 Monate nach Abschluss einschränkt und Advent International einen Sitz im Vorstand gewährt, solange es ≥5% der Aktien hält; (ii) eine Änderung, die die Größe des Waystar-Vorstands von 12 auf 13 erhöht, um den Advent-Nominierten aufzunehmen; und (iii) einen Beitritt zur Registrierungsrechtsvereinbarung, der Advent zwei Kurzform-Anmeldeanmeldungen und Piggyback-Rechte 18 Monate nach Abschluss gewährt.

Eine Pressemitteilung mit vorläufigen Ergebnissen des zweiten Quartals des Geschäftsjahres 2025 wurde als Anlage 99.1 gemäß den Punkten 2.02 und 7.01 eingereicht.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Bonstein Sara

(Last) (First) (Middle)
700 US HIGHWAY 202/206

(Street)
BRIDGEWATER NJ 08807

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
INSMED Inc [ INSM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
07/21/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/21/2025 M(1) 3,443 A $26.46 87,460 D
Common Stock 07/21/2025 M(1) 11,455 A $28.88 98,915 D
Common Stock 07/21/2025 M(1) 15,890 A $29.13 114,805 D
Common Stock 07/21/2025 M(1) 17,100 A $34.03 131,905 D
Common Stock 07/21/2025 S(1) 32,090 D $102.38(2) 99,815 D
Common Stock 07/21/2025 S(1) 26,310 D $103.03(3) 73,505 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $26.46 07/21/2025 M(1) 3,443 (4) 05/12/2031 Common Stock 3,443 $0 8,580 D
Stock Option (right to buy) $28.88 07/21/2025 M(1) 11,455 (4) 02/03/2030 Common Stock 11,455 $0 0 D
Stock Option (right to buy) $29.13 07/21/2025 M(1) 15,890 (5) 01/04/2034 Common Stock 15,890 $0 47,670 D
Stock Option (right to buy) $34.03 07/21/2025 M(1) 17,100 (4) 01/07/2031 Common Stock 17,100 $0 0 D
Explanation of Responses:
1. This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 5, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
2. This is the weighted average sales price representing 32,090 shares sold at prices ranging from $101.77 to $102.76 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
3. This is the weighted average sales price representing 26,310 shares sold at prices ranging from $102.77 to $103.37 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
4. The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable.
5. The options become exercisable based on the following vesting schedule: 25% vest on the first anniversary of the grant date and an additional 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.
Remarks:
/s/ Sara Bonstein, by Michael A. Smith as Attorney-in-fact 07/23/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What is Waystar (WAY) acquiring?

Waystar will acquire Iodine Software Holdings, Inc. via a series of mergers.

What is the total purchase price of the Iodine deal?

The enterprise value is approximately $1.25 billion, funded by $625 million cash and 16,751,54 new shares.

When must the merger close?

Either party may terminate if the transaction is not closed by 23-Nov-2025.

Will Advent International have board representation?

Yes. Advent may nominate one director while it and affiliates own at least 5% of Waystar shares.

How long are new shares locked up?

Transfer restrictions last 18 months for Advent and the Iodine CEO, 12 months for certain holders, and 6 months for others.

Is the press release with preliminary Q2-25 results part of the filing?

Yes, it is furnished as Exhibit 99.1 under Items 2.02 and 7.01.
Insmed Inc

NASDAQ:INSM

INSM Rankings

INSM Latest News

INSM Latest SEC Filings

INSM Stock Data

19.55B
187.30M
0.98%
112.55%
8.07%
Biotechnology
Pharmaceutical Preparations
Link
United States
BRIDGEWATER